InsiderTrades

Form 4 for ARQT Arcutis Biotherapeutics, Inc.

Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-13 · accession 0001787306-24-000014 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-02-15 2024-02-13 ARQT Smither John W CFO A - Grant — +11.4K 11.4K New —
DM 2024-02-15 2024-02-13 ARQT Smither John W CFO D - Sale to Iss — -34.1K 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-02-13 A A 2,793 — 2,793 D — — (F1) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024.
2 Common Common Stock 2024-02-13 A A 8,572 — 11,365 D — — (F2) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024.
3 Derivative Stock Option (right to buy) 2024-02-13 D D 8,379 — 0 D $27.61 · — to 2025-03-31 8,379 Common Stock (F1) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on February 27, 2020, and received in exchange for the option, these Restricted Stock Units ("RSUs") that vest in four equal quarterly installments commencing May 1, 2024. (F4) This option is fully vested.
4 Derivative Stock Option (right to buy) 2024-02-13 D D 25,718 — 0 D $32.44 · — to 2025-03-31 25,718 Common Stock (F2) On February 13, 2024, the Issuer canceled, pursuant to the Issuer's option exchange program, an option granted to the Reporting Person on March 3, 2021, and received in exchange for the option, these RSUs that vest in eight equal quarterly installments commencing May 1, 2024. (F5) This option is fully vested.